Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

被引：23

作者：

Almeida, Antonio M. ^{[1
]}

Prebet, Thomas ^{[2
,3
]}

Itzykson, Raphael ^{[4
]}

Ramos, Fernando ^{[5
]}

Al-Ali, Haifa ^{[6
]}

Shammo, Jamile ^{[7
]}

Pinto, Ricardo ^{[8
]}

Maurillo, Luca ^{[9
]}

Wetzel, Jaime ^{[10
]}

Musto, Pellegrino ^{[11
]}

Van De Loosdrecht, Arjan A. ^{[12
]}

Costa, Maria Joao ^{[13
]}

Esteves, Susana ^{[1
]}

Burgstaller, Sonja ^{[14
]}

Stauder, Reinhard ^{[15
]}

Autzinger, Eva M. ^{[16
]}

Lang, Alois ^{[17
]}

Krippl, Peter ^{[18
]}

Geissler, Dietmar ^{[19
]}

Francisco Falantes, Jose ^{[20
]}

Pedro, Carmen ^{[21
]}

Bargay, Joan ^{[22
]}

Deben, Guillermo ^{[23
]}

Garrido, Ana ^{[24
]}

Bonanad, Santiago ^{[25
]}

Diez-Campelo, Maria ^{[26
]}

Thepot, Sylvain ^{[27
]}

Ades, Lionel ^{[4
]}

Sperr, Wolfgang R. ^{[28
,29
]}

Valent, Peter ^{[28
,29
]}

Fenaux, Pierre ^{[4
]}

Sekeres, Mikkael A. ^{[10
]}

Greil, Richard ^{[30
,31
,32
,33
]}

Pleyer, Lisa ^{[30
,31
,32
,33
]}

机构：

[1] IPOL, P-1200795 Lisbon, Portugal

[2] Inst Paoli Calmettes, Marseille, France

[3] Yale New Haven Med Ctr, New Haven, CT 06512 USA

[4] Paris Diderot Univ, Hop St Louis, AP HP, F-75010 Paris, France

[5] Hosp Univ Leon, Leon 24071, Spain

[6] Univ Hosp Halle, D-06120 Halle, Germany

[7] Rush Univ, Med Ctr, Chicago, IN 60612 USA

[8] Hosp Sao Joao, P-4200319 Oporto, Portugal

[9] Univ Tor Vergata, I-00173 Rome, Italy

[10] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA

[11] Referral Canc Ctr Basilicata, RCCS CROB, I-85028 Rionero In Vulture, Pz, Italy

[12] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[13] Hosp Santa Maria, Ctr Hosp Lisboa Norte, P-1649035 Lisbon, Portugal

[14] Hosp Wels Grieskirchen, Dept Internal Med 4, A-4600 Wels, Austria

[15] Innsbruck Med Univ, Dept Internal Med Haematol & Oncol 5, A-6020 Innsbruck, Austria

[16] Wilhelminenspital Stadt Wien, Ctr Oncol & Hematol, Dept Internal Med 1, A-1160 Vienna, Austria

[17] Hosp Feldkirch, Internal Med, A-6800 Feldkirch, Austria

[18] Hosp Furstenfeld, Dept Internal Med, A-8280 Furstenfeld, Austria

[19] Klinikum Klagenfurt Worthersee, Dept Internal Med, A-9020 Portschach Am Worthersee, Austria

[20] Hosp Univ Virgen Rocio, Seville 41013, Spain

[21] Hosp Mar, Barcelona 08003, Spain

[22] Hosp Son Llatzer, Palma De Mallorca 07198, Spain

[23] Hosp Univ, La Coruna 15006, Spain

[24] Hosp Santa Creu & Sant Pau, Barcelona 08026, Spain

[25] Hosp Univ Ribera, Alzira 46600, Spain

[26] Hosp Univ Salamanca, Salamanca 37007, Spain

[27] CHU, F-49100 Angers, France

[28] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria

[29] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, A-1090 Vienna, Austria

[30] Paracelsus Med Univ, Med Dept 3, A-5020 Salzburg, Austria

[31] Salzburg Canc Res Inst, A-5020 Salzburg, Austria

[32] Canc Cluster Salzburg, A-5020 Salzburg, Austria

[33] Arbeitsgemeinschaft Medikamentose Tumortherapie A, A-5020 Salzburg, Austria

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2017年 / 18卷 / 04期

关键词：

acute erythroleukemia; azacitidine; decitabine; ACUTE MYELOID-LEUKEMIA; CONVENTIONAL CARE REGIMENS; ACUTE ERYTHROID LEUKEMIA; HEALTH-ORGANIZATION CLASSIFICATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; STEM-CELL TRANSPLANTATION; MYELODYSPLASTIC SYNDROMES; OLDER PATIENTS; OPEN-LABEL; COMPLETE REMISSION;

D O I：

10.3390/ijms18040837

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p <= 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

引用

页数：16

共 63 条

[41] Acute erythroleukemia - Evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis [J].

Mazzella, FM ;

Kowal-Vern, A ;

Shrit, MA ;

Wibowo, AL ;

Rector, JT ;

Cotelingam, JD ;

Collier, J ;

Mikhael, A ;

Cualing, H ;

Schumacher, HR .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1998, 110 (05) :590-598

[42] High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24) [J].

Micci, F. ;

Thorsen, J. ;

Panagopoulos, I. ;

Nyquist, K. B. ;

Zeller, B. ;

Tierens, A. ;

Heim, S. .

LEUKEMIA, 2013, 27 (04) :980-982

[43]

OLOPADE OI, 1992, BLOOD, V80, P2873

[44] Genomic Classification and Prognosis in Acute Myeloid Leukemia [J].

Papaemmanuil, Elli ;

Gerstung, Moritz ;

Bullinger, Lars ;

Gaidzik, Verena I. ;

Paschka, Peter ;

Roberts, Nicola D. ;

Potter, Nicola E. ;

Heuser, Michael ;

Thol, Felicitas ;

Bolli, Niccolo ;

Gundem, Gunes ;

Van Loo, Peter ;

Martincorena, Inigo ;

Ganly, Peter ;

Mudie, Laura ;

McLaren, Stuart ;

O'Meara, Sarah ;

Raine, Keiran ;

Jones, David R. ;

Teague, Jon W. ;

Butler, Adam P. ;

Greaves, Mel F. ;

Ganser, Arnold ;

Doehner, Konstanze ;

Schlenk, Richard F. ;

Doehner, Hartmut ;

Campbell, Peter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (23) :2209-2221

[45]

Pierdomenico Francesca, 2013, Leuk Res Rep, V2, P41, DOI 10.1016/j.lrr.2013.04.001

[46] Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications [J].

Pleyer, Lisa ;

Burgstaller, Sonja ;

Stauder, Reinhard ;

Girschikofsky, Michael ;

Sill, Heinz ;

Schlick, Konstantin ;

Thaler, Josef ;

Halter, Britta ;

Machherndl-Spandl, Sigrid ;

Zebisch, Armin ;

Pichler, Angelika ;

Pfeilstoecker, Michael ;

Autzinger, Eva-Maria ;

Lang, Alois ;

Geissler, Klaus ;

Voskova, Daniela ;

Geissler, Dietmar ;

Sperr, Wolfgang R. ;

Hojas, Sabine ;

Rogulj, Inga M. ;

Andel, Johannes ;

Greil, Richard .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9

[47] Digging deep into "dirty'' drugs - modulation of the methylation machinery [J].

Pleyer, Lisa ;

Greil, Richard .

DRUG METABOLISM REVIEWS, 2015, 47 (02) :252-279

[48] Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group [J].

Pleyer, Lisa ;

Burgstaller, Sonja ;

Girschikofsky, Michael ;

Linkesch, Werner ;

Stauder, Reinhard ;

Pfeilstocker, Michael ;

Schreder, Martin ;

Tinchon, Christoph ;

Sliwa, Thamer ;

Lang, Alois ;

Sperr, Wolfgang R. ;

Krippl, Peter ;

Geissler, Dietmar ;

Voskova, Daniela ;

Schlick, Konstantin ;

Thaler, Josef ;

Machherndl-Spandl, Sigrid ;

Theiler, Georg ;

Eckmuellner, Otto ;

Greil, Richard .

ANNALS OF HEMATOLOGY, 2014, 93 (11) :1825-1838

[49] Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival [J].

Pleyer, Lisa ;

Germing, Ulrich ;

Sperr, Wolfgang R. ;

Linkesch, Werner ;

Burgstaller, Sonja ;

Stauder, Reinhard ;

Girschikofsky, Michael ;

Schreder, Martin ;

Pfeilstocker, Michael ;

Lang, Alois ;

Sliwa, Thamer ;

Geissler, Dietmar ;

Schlick, Konstantin ;

Placher-Sorko, Gudrun ;

Theiler, Georg ;

Thaler, Josef ;

Mitrovic, Martina ;

Neureiter, Daniel ;

Valent, Peter ;

Greila, Richard .

LEUKEMIA RESEARCH, 2014, 38 (04) :475-483

[50] Azacitidine in patients with WHO-defined AML - Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group [J].

Pleyer, Lisa ;

Stauder, Reinhard ;

Burgstaller, Sonja ;

Schreder, Martin ;

Tinchon, Christoph ;

Pfeilstocker, Michael ;

Steinkirchner, Susanne ;

Melchardt, Thomas ;

Mitrovic, Martina ;

Girschikofsky, Michael ;

Lang, Alois ;

Krippl, Peter ;

Sliwa, Thamer ;

Egle, Alexander ;

Linkesch, Werner ;

Voskova, Daniela ;

Angermann, Hubert ;

Greil, Richard .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

← 1 2 3 4 5 6 7 →